Table 2.

Treatment discontinuation by cycle

	6M group (n = 642)		12M group (n = 636)
	n	(%)	n	(%)
No. of patients discontinued
During cycle 1	23	(3.6%)	25	(3.9%)
During cycle 2	21	(3.3%)	32	(5.0%)
During cycle 3	37	(5.8%)	33	(5.2%)
During cycle 4	21	(3.3%)	26	(4.1%)
During cycle 5	23	(3.6%)	20	(3.1%)
During cycle 6	21	(3.3%)	13	(2.0%)
During cycle 7	23	(3.6%)	28	(4.4%)
During cycle 8	14	(2.2%)	42	(6.6%)
During cycle 9	–	–	19	(3.0%)
During cycle 10	–	–	15	(2.4%)
During cycle 11	–	–	16	(2.5%)
During cycle 12	–	–	10	(1.6%)
During cycle 13	–	–	14	(2.2%)
During cycle 14	–	–	14	(2.2%)
During cycle 15	–	–	25	(3.9%)
During cycle 16	–	–	11	(1.7%)
No. of patients completed 8 cycles of capecitabine	459	(71.5%)	456	(71.7%)
No. of patients completed 16 cycles of capecitabine	–	–	293	(46.1%)